Nurix Therapeutics, Inc.
Clinical trials sponsored by Nurix Therapeutics, Inc., explained in plain language.
-
New drug cocktail aims to tackle tough blood cancers
Disease control Not yet recruitingThis study tests a new drug called NX-5948 (bexobrutideg) combined with other medicines (venetoclax, and possibly rituximab or obinutuzumab) in adults with B-cell lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma. The goal is to see if the combination is safe …
Phase: PHASE1, PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for hard-to-treat blood cancers: phase 3 trial pits NX-5948 against standard therapy
Disease control Not yet recruitingThis study compares two drugs, NX-5948 and pirtobrutinib, in about 620 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding after prior treatment with a BTK inhibitor. The main goal is to see which drug…
Phase: PHASE3 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC